935-77-3

Basic information

• Product Name: 1H-Inden-1-one, 2,3-dihydro-3-methyl-, (3S)-
• CAS NO: 935-77-3
• Molecular Formula: C10H10O
• Molecular Weight: 146.189
• Mol File: 935-77-3.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: 1H-Inden-1-one, 2,3-dihydro-3-methyl-, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Inden-1-one, 2,3-dihydro-3-methyl-, (3S)-(935-77-3)
• EPA Substance Registry System: 1H-Inden-1-one, 2,3-dihydro-3-methyl-, (3S)-(935-77-3)

Safety Data

• Hazardous Substances Data: 935-77-3(Hazardous Substances Data)

Usage

General Description

1H-Inden-1-one, 2,3-dihydro-3-methyl-, (3S)-, also known as 3S-2,3-dihydro-3-methyl-1H-inden-1-one, is a chemical compound with the molecular formula C10H10O. It is a chiral molecule, meaning it has a specific spatial arrangement of atoms, and the (3S)- designation refers to its stereochemistry. 1H-Inden-1-one, 2,3-dihydro-3-methyl-, (3S)- is commonly used in the production of fragrances and perfumes due to its pleasant odor. It may also have potential applications in pharmaceuticals and organic synthesis. Additionally, it is a colorless to pale yellow liquid at room temperature and is relatively stable under normal conditions.

Upstream product

• 4593-90-2 (S)-2-phenylbutanoic acid 
• 68679-84-5 (S)-3-phenyl butyric acid chloride 
• 40774-41-2 3-Bromoindan-1-one 
• 74-88-4 methyl iodide 
• 23417-79-0 2-(1-methylethenyl)benzaldehyde 
• 32523-78-7 (1R,3S)-3-methyl-2,3-dihydro-1H-inden-1-ol 
• 6072-57-7 3-methylindanone 
• 40138-16-7 2-formylbenzene boronic acid 
• 83-33-0 inden-1-one 
• 113675-84-6 (4R,5S)-1,5-Dimethyl-4-phenyl-3-((S)-3-phenyl-butyryl)-imidazolidin-2-one 
• 4593-90-2 3-phenylbutyric acid 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 767-58-8 (-)-(S)-1-methylindane 
• 164265-05-8 (S)-2-(3-hydroxy-1-methylpropyl)phenol 
• 159650-89-2 (+)-(S)-2-sec-butylphenol 
• 1286745-30-9 (S,S)-1,4-bis((5-sec-butyl-4-hydroxy-3-formylphenyl)ethynyl)benzene 
• 1286745-35-4 (S)-3-sec-butyl-2-hydroxy-5-iodobenzaldehyde 
• 1286745-34-3 (S)-3-sec-butyl-2-hydroxybenzaldehyde 
• 1286745-33-2 (S)-benzoic acid 2-sec-butylphenyl ester 
• 1286745-32-1 (S)-benzoic acid 2-(3-iodo-1-methylpropyl)phenyl ester 
• 1286745-31-0 (S)-benzoic acid 2-(3-hydroxy-1-methylpropyl)phenyl ester 
• 82252-89-9 (R,R)-2t-Benzyl-1r-methyl-3-oxo-2c-indancarbonsaeure-ethylester 
• 82252-91-3 (1R,2S)-2c-(Acetoxymethyl)-2t-benzyl-1r-methylindan 
• 82309-93-1 (2S,3R)-2t-Benzyl-2c-(hydroxymethyl)-3r-methyl-1t-indanol 
• 82309-96-4 (1R,2S)-2t-Benzyl-1r-methyl-2c-indancarbonsaeure 
• 82309-95-3 (1R,2S)-2t-Benzyl-1r-methyl-2c-indanmethanol 

Relevant articles and documents

Mild, efficient friedel-Crafts acylations from carboxylic acids using cyanuric chloride and AlCl3

(Chemical Equation Presented) A mild method for Friedel-Crafts acylation with aromatic and aliphatic carboxylic acids using cyanuric chloride, pyridine, and AlCl3 was developed. Both inter- and intramolecular acylations were achieved at room temperature in high yield and in very short reaction times.

CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS

The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

Cobalt-catalyzed enantioselective intramolecular hydroacylation of ketones and olefins

Cobalt-chiral diphoshine catalytic systems promote intramolecular hydroacylation reactions of 2-acylbenzaldehydes and 2-alkenylbenzaldehydes to afford phthalide and indanone derivatives, respectively, in moderate to good yields with high enantioselectivities. The ketone hydroacylation did not exhibit a significant H/D kinetic isotope effect (KIE) with respect to the aldehyde C-H bond, indicating that C-H activation would not be involved in the rate-limiting step.